Arkolith/Insider Trading/INXB/Form 4

Lappe Mark

Chief Executive Officer, DirectorInhibrx Biosciences, Inc. (INXB) · full profile →Form 4 · filed May 30, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 29, 2024Grant(A)15K——15K
May 29, 2024Grant(A)125K——125K
May 29, 2024Grant(A)622K——622K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 30, 2024Grant(A)300K—$0300K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950142-24-001493) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML